MILPITAS, Calif.--(BUSINESS WIRE)--Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling technologies designed to mimic the normal arterial function after cardiovascular and peripheral vascular disease intervention, announced today it will unveil a game-changing metallic drug eluting stent (DES) platform at this year’s Transcatheter Cardiovascular Therapeutics (TCT) conference in Denver, which runs from October 29 – November 2.
DynamX is a 71 microns thin metallic DES designed to match the ease of use and acute performance of state-of-the-art DES. Unlike DES, however, DynamX allows the vessel to exhibit its normal pulsatile motion and adaptive remodeling capabilities. Elixir will be sharing for the first time the concept, design, data from preclinical testing, and clinical program for its DynamX TM Stent at a signature evening symposium on Monday, October 30th 6:00 – 8:00 pm.
“DynamX ushers a new era of transformation from the current metallic stents which cage the vessel into stents that allow pulsatile motion and adaptive remodeling, mimicking the normal vessel function of patients,” said Motasim Sirhan, founder, and CEO of Elixir Medical. “Elixir continues its commitment to developing breakthrough adaptive remodeling technologies to better address patient needs around the world beyond the capabilities of today’s technologies.”
Elixir continues to advance its fully bioresorbable scaffold programs and will present its latest trial results throughout TCT.
Below are the details for Elixir programs and activities at TCT 2017 in Mountain Daylight Time (MDT):
Monday, October 30:
11 a.m. – Mile High Ballroom 2A-3A, Ballroom Level
Drug Eluting
Scaffold with an Absorbable Platform for Primary Lower Extremity
Arterial Revascularization: DESappear Study Initial Results with
Prava
Thomas Zeller, MD, Universitäts-Herzzentrum Freiburg, Bad
Krozingen, Germany
6 p.m. – 8:00 p.m., Hyatt Regency Centennial
Ballroom D-E
ELIXIR SYMPOSIUM: DynamX TM Redefining
Interventional Cardiology
Co-Chairs and Faculty
- Martin B. Leon MD, New York-Presbyterian Hospital/Columbia University Medical Center, New York, NY, USA
- Dean J. Kereiakes, MD, The Christ Hospital, Cincinnati, OH, USA
- Stefan Verheye, MD, PH.D., Antwerp Cardiovascular Centre, ZNA, Antwerp, Belgium
- Roxana Mehran, MD, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Agenda
- PCI vision and Introducing the DynamX stent
- DynamX Pre-Clinical Testing
- Limitations of Current DES: DynamX in perspective
- DynamX Clinical Program Overview
- Q & A
- Take Home Message
Attendees are encouraged to register early to attend the Elixir unveiling on Monday evening.
Tuesday, October 31:
9:54 a.m. – Moderated Posters 4, Exhibit Hall, Exhibit Level
Multi-Center
Evaluation of a Novel 120 µm Novolimus-Eluting, Fully Bioresorbable
Coronary Scaffold: First Report of 6-month Imaging and 12-Month
Clinical Results
Stefan Verheye, MD, PHD, Antwerp Cardiovascular
Centre, ZNA, Antwerp, Belgium
10:06 a.m. - Moderated Posters 4, Exhibit Hall, Exhibit Level
Multi-Center,
Post-marketing Evaluation of the Elixir DESolve Novolimus Eluting
Bioresorbable Coronary Stent System: 24-month Results from the
DESolve PMCF Study
Holger Nef, MD, Ph.D., University Hospital
Giessen, Giessen, Germany
12:06 p.m. - Moderated Posters 3, Exhibit Hall, Exhibit Level
Drug
Eluting Scaffold with an Absorbable Platform for Primary Lower Extremity
Arterial Revascularization – DESappear Study Initial Results
Marc
Bosiers, MD, St. Blasius Hospital, Dendermonde, Belgium
1:45 p.m. – Room 709/711, Meeting Room Level
Prospective,
Multicenter Evaluation of the DESolve®
Novolimus-Eluting Bioresorbable Coronary Scaffold - Imaging Outcomes
and Five-Year Clinical and Imaging Results
Stefan Verheye, MD,
PH.D., Antwerp Cardiovascular Centre, ZNA, Antwerp, Belgium
3:21 p.m. – Room 210, Meeting Room Level, Virtual Didactic
The
DESyne Novolimus-Eluting Coronary Stent: Results From the Excella
Trials
Javaid Iqbal, MD, South Yorkshire Cardiothoracic Centre,
Sheffield Teaching Hospitals NHS Foundation Trust Sheffield, United
Kingdom
4:33 p.m. – Mile High Ballroom 4E-4F, Ballroom Level
DESolve Nx,
Cx, and Amity: A Family of Progressively Thinner-Strut PLLA-Based
BRS With Novel Properties
Stefan Verheye, MD, PH.D., Antwerp
Cardiovascular Centre, ZNA, Antwerp, Belgium
7:05 p.m. – Hyatt Regency Denver at Colorado Convention Center
Continental Ballroom F-H
A “Novel” Metallic DES with
Bioresorbable Polymer- The Elixir DynamX Program
Martin B. Leon
MD, New York-Presbyterian Hospital/Columbia University Medical Center,
New York, NY, USA
7:40 p.m. – Hyatt Regency Denver at Colorado Convention Center
Continental Ballroom F-H
The BRS Landscape: Where do we
Stand? (ABSORB, MAGNITUDE, DESolve, FANTOM, and DREAMS-2G)
Gregg W.
Stone, MD, New York-Presbyterian Hospital/Columbia University Medical
Center, New York, NY, USA
About Elixir Medical Corporation
Elixir Medical Corporation, a privately funded company based in Milpitas, California, has developed the broadest portfolio of coronary stents and scaffolds including DESyne, DESyne BD, DESolve, DESolve CX, DESolve NXT, Prava, and the breakthrough DynamX product platform. The company's next-generation drug-eluting stent systems and bioresorbable coronary scaffolds are designed to mimic the normal pulsatile motion and adaptive remodeling capabilities of the vessel after intervention to better address patient needs. For more information, visit www.elixirmedical.com.